Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5157326 | 0.95 | MAPT (0.41) | TSHRACHERAPGEF4KAT6AALDH1A1 | |
| SCHEMBL305238 | 0.83 | TSHR (0.43) | TSHRACHERAPGEF4KAT6AALDH1A1 | |
| SCHEMBL4533183 | 0.77 | TSHR (0.47) | TSHRACHERAPGEF4KAT6AALDH1A1 | |
| SCHEMBL29468592 | 0.77 | ALDH1A1 (0.55) | TSHRACHERAPGEF4ALDH1A1KDM4E | |
| SCHEMBL475089 | 0.77 | ALDH1A1 (0.55) | TSHRACHERAPGEF4ALDH1A1KDM4E | |
| Water SCHEMBL9476427 | 0.76 | ALDH1A1 (0.42) | TSHRACHERAPGEF4ALDH1A1KDM4E | |
| Potassium Ion SCHEMBL340525 | 0.76 | HSD11B1 (0.42) | TSHRACHERAPGEF4ALDH1A1KDM4E | |
| Water SCHEMBL1739275 | 0.76 | MYC (0.52) | TSHRACHERAPGEF4KAT6AALDH1A1 | |
| Water SCHEMBL3917281 | 0.76 | MYC (0.52) | TSHRACHERAPGEF4KAT6AALDH1A1 | |
| Water SCHEMBL8126703 | 0.76 | MYC (0.52) | TSHRACHERAPGEF4KAT6AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3648773-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | Aposense Ltd. (IL) | 2020-05-13 | — | — | EP | disclosed |
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-05-02 | — | — | US | disclosed |
| EP-3463381-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | The Trustees of Columbia University in the City of New York (US) | 2019-04-10 | — | — | EP | disclosed |
| US-10195286-B2 | Compounds and methods for trans-membrane delivery of molecules | APOSENSE LTD. (IL) | 2019-02-05 | — | — | US | disclosed |
| WO-2019008574-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-01-10 | — | — | WO | disclosed |
| US-20190008976-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | APOSENSE LTD. (IL) | 2019-01-10 | — | — | US | disclosed |
| WO-2017205336-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20160122383-A1 | Peptide Ligation | THE UNIVERSITY OF SYDNEY (AU) | 2016-05-05 | — | — | US | disclosed |
| EP-3004134-A1 | PEPTIDE LIGATION | The University Of Sydney (AU) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014194361-A1 | PEPTIDE LIGATION | THE UNIVERSITY OF SYDNEY (AU) | 2014-12-11 | — | — | WO | disclosed |
| US-7229751-B2 | Silver salt photothermographic dry imaging material and image forming method using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7022470-B2 | Photothermographic imaging material | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20050136366-A1 | Silver salt photothermographic dry imaging material and image forming method using the same | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2005-06-23 | — | — | US | disclosed |
| US-20040224266-A1 | Photothermographic imaging material | KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) | 2004-11-11 | — | — | US | disclosed |
| EP-1462854-A1 | Photothermographic imaging material | Konica Minolta Medical & Graphic Inc. (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-5340833-A | Antiarthritic, antiinflammatory, antitumor agents | EISAI CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| US-5296505-A | Reacting dithianepropenol with ethynyl-beta-ionol in presence of organomagnesium compound, hydrogenating triple bond, reducing diol with low-valency titanium | L'OREAL (FR) | 1994-03-22 | — | — | US | disclosed |
| EP-0568289-A2 | Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors | Eisai Co., Ltd. (JP) | 1993-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195286-B2 | Compounds and methods for trans-membrane delivery of molecules | SLCO2B1, SLCO1B1, ABCB4 | TSHR 1201/4885ACHE 4878/4885RAPGEF4 3249/4885 |
| US-20160122383-A1 | Peptide Ligation | PTMS, PTMA, QPCTL | TSHR 1899/4885ACHE 3052/4885RAPGEF4 2431/4885 |
| US-20190125884-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | ABCB4, ABCB1, SLCO2B1 | TSHR 1669/4885ACHE 4882/4885RAPGEF4 2802/4885 |
| US-20190008976-A1 | COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES | SLCO2B1, SLCO1B1, ABCB4 | TSHR 1201/4885ACHE 4878/4885RAPGEF4 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.